肠道宏蛋白质组学揭示1型糖尿病高风险者宿主-微生物互作
该横断面分析对近期发病1型糖尿病者、胰岛自身抗体阳性者、低风险抗体阴性者及健康者的粪便进行宏蛋白质组学与微生物测序整合分析,发现宿主和微生物蛋白可区分新发及抗体阳性者与低风险者,提示1型糖尿病存在肠道炎症增加和屏障功能下降,且胰腺外分泌功能障碍在新发1型糖尿病中存在,并首次显示该障碍在发病前高风险个体中已出现。
要点
- 宿主和微生物蛋白可区分新发及胰岛自身抗体阳性者与低风险者。
- 新发1型糖尿病患者中与胰腺外分泌、炎症和黏膜功能相关的宿主蛋白流行率显著改变。
- 与黏液屏障、微绒毛黏附和胰腺外分泌功能相关的微生物 taxa 在新发1型糖尿病中耗竭。
核心结论
- 1型糖尿病患者肠道炎症增加且屏障功能下降。
- 胰腺外分泌功能障碍见于新发1型糖尿病,并首次显示在发病前高风险个体中已存在。
- 粪便中独特的1型糖尿病相关特征可能用于监测疾病进展或治疗反应。
研究设计与样本
- 横断面分析,纳入近期发病1型糖尿病者33例、胰岛自身抗体阳性者17例、低风险抗体阴性者29例及健康者22例的粪便样本。
- 采用宏蛋白质组学分析鉴定肠道和胰腺来源的宿主及微生物蛋白,并与测序为基础的微生物谱整合。
主要发现
- 宿主蛋白和微生物蛋白均可区分新发及胰岛自身抗体阳性者与低风险者。
- 与胰腺外分泌输出、炎症和黏膜功能相关的宿主蛋白流行率存在显著改变。
- 整合分析显示,与维持黏液屏障、微绒毛黏附和胰腺外分泌功能相关的宿主蛋白相关的微生物 taxa 在新发1型糖尿病患者中耗竭。
临床怎么用
- 粪便宏蛋白质组学特征可能作为监测1型糖尿病疾病进展或针对恢复健康微生物群治疗反应的潜在手段。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dysbiosis of the gut microbiota has been linked to disease pathogenesis in type 1 diabetes, yet the functional consequences to the host of this dysbiosis are unknown. We investigated the functional interactions between the microbiota and the host associated with type 1 diabetes disease risk. RESEARCH DESIGN AND METHODS: We performed a cross-sectional analysis of stool samples from subjects with recent-onset type 1 diabetes (n = 33), islet autoantibody-positive subjects (n = 17), low-risk autoantibody-negative subjects (n = 29), and healthy subjects (n = 22). Metaproteomic analysis was used to identify gut- and pancreas-derived host and microbial proteins, and these data were integrated with sequencing-based microbiota profiling. RESULTS: Both human (host-derived) proteins and microbial-derived proteins could be used to differentiate new-onset and islet autoantibody-positive subjects from low-risk subjects. Significant alterations were identified in the prevalence of host proteins associated with exocrine pancreas output, inflammation, and mucosal function. Integrative analysis showed that microbial taxa associated with host proteins involved in maintaining function of the mucous barrier, microvilli adhesion, and exocrine pancreas were depleted in patients with new-onset type 1 diabetes. CONCLUSIONS: These data support that patients with type 1 diabetes have increased intestinal inflammation and decreased barrier function. They also confirmed that pancreatic exocrine dysfunction occurs in new-onset type 1 diabetes and show for the first time that this dysfunction is present in high-risk individuals before disease onset. The data identify a unique type 1 diabetes-associated signature in stool that may be useful as a means to monitor disease progression or response to therapies aimed at restoring a healthy microbiota.
引用
- Gavin PG, Mullaney JA, Loo D, et al. Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes. Diabetes Care. 2018. PMID: 30100563. doi:10.2337/dc18-0777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。